



Koala cathelicidin PhciCath5 has antimicrobial activity, 1 
including against Chlamydia pecorum 2 
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Devastating fires in Australia over 2019-20 decimated native fauna and flora, including koalas. 23 
The resulting population bottleneck, combined with significant loss of habitat, increases the 24 
vulnerability of remaining koala populations to threats which include such as disease. 25 
Chlamydia is one disease which causes significant morbidity and mortality in koalas. The 26 
predominant pathogenic species in koalas, Chlamydia pecorum, causes severe ocular, 27 
urogenital and reproductive tract disease. In marsupials, including the koala, gene expansions 28 
of an antimicrobial peptide family known as cathelicidins have enabled protection of 29 
immunologically naïve pouch young during early development. We propose that koala 30 
cathelicidins are active against Chlamydia and other bacteria and fungi. Here we describe ten 31 
koala cathelicidins, five of which contained full length coding sequences that were widely 32 
expressed in tissues throughout the body. Focusing on these five, we investigate their 33 
antimicrobial activity against two koala C. pecorum isolates from distinct serovars; MarsBar 34 
and IPTaLE, as well as other bacteria and fungi. One cathelicidin, PhciCath5, rapidly 35 
inactivated C. pecorum IPTaLE and MarsBar elementary bodies and significantly reduced the 36 
number of inclusions compared to the control (p<0.0001). Despite evidence of cathelicidin 37 
expression within tissues known to be infected by Chlamydia, natural PhciCath5 38 
concentrations may be inadequate in vivo to prevent or control C. pecorum infections in koalas. 39 
PhciCath5 also displayed antimicrobial activity against fungi and Gram negative and positive 40 
bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Electrostatic 41 
interactions likely drive PhciCath5 adherence to the pathogen cell membrane, followed by 42 
membrane permeabilisation leading to cell death. Although, Aactivity against E. coli  was 43 
reduced in the presence of 10% serum and 20% whole blood. Future modification of the 44 
PhciCath5 peptide to enhance activity, including in the presence of serum/blood, may provide 45 





The koala (Phascolarctos cinereus) is an iconic Australian marsupial and the last surviving 48 
member of the Phascolarctidae. Marsupials are one of three mammalian lineages, the others 49 
being eutherian mammals such as humans, and monotremes such as the platypus. Marsupials 50 
differ from other mammals in a number of key anatomical and physiological traits, many of 51 
which are involved in reproduction and development [1]. Koalas are mostly arboreal 52 
marsupials that subsist on a strict diet of Eucalyptus leaves [1]. Typical of marsupials, koalas 53 
have a short gestation period of up to 35 days and give birth to altricial young that remain in 54 
the pouch for 9 months [1].  55 
 56 
Fires devastated large swathes of Australia in 2019-20, burning through at least 11 million 57 
hectares (1.1x1011 m2), destroying crucial habitat of already vulnerable and threatened species, 58 
and driving many to the brink of extinction [2, 3]. Estimates suggest nearly three billion animals 59 
were killed or impacted by the fires [4]. In response, the Australian Government identified 119 60 
priority species severely impacted by the fires which require urgent management intervention, 61 
one of which was the koala [3]. Prior to this catastrophic event, koala populations were already 62 
in decline along the east coast of Australia due to multiple threats including habitat loss, climate 63 
change, and disease [5, 6]. The 2019-20 fires further decimated these populations; with at least 64 
3.5 million hectares(3.5 x 1010 m2), or 25%, of koala suitable habitat in eastern NSW affected 65 
by fire [7]. The resulting genetic bottleneck, combined with substantial habitat destruction by 66 
the fires, leaves remaining populations especially vulnerable to new and existing threats, 67 
including such as disease [5, 8] 68 
 69 
Three main diseases infect koalas; koala retrovirus [9], the fungus,i Cryptococcus [10], and the 70 




infection, is a major contributing factor to the decline and long-term viability of koala 72 
populations [5]. Chlamydia are intracellular, bi-phasic, Gram-negative bacteria which infect a 73 
wide range of hosts including humans, livestock, and wildlife [11]. Chlamydia pecorum is 74 
principally responsible for chlamydiosis in koalas, and causes both mild and severe disease [6, 75 
12]. Clinical manifestations include ocular disease leading to blindness, urogenital disease 76 
resulting in cystitis and infertility, and respiratory disease [5]. The prevalence of infection 77 
varies, but is as high ascan reach 90% in koala populations in Queensland, New South Wales, 78 
and Victoria [5, 6].  79 
 80 
Significant research over the past decade has culminated in a promising C. pecorum vaccine 81 
for koalas (reviewed in [13]). However, limitations remain regarding long-term protection 82 
against reinfection [14], hence research is ongoing and. As such, treatment remains an essential 83 
component of the response to chlamydiosis in koalas. Treating chlamydiosis in koalas can be 84 
difficult as macrolide and tetracycline antibiotics commonly used in humans cause 85 
gastrointestinal dysbiosis, which can be fatal [15, 16]. Chloramphenicol and enrofloxacin are 86 
commonly used in koalas, and pharmacokinetic studies have aided in developing koala-specific 87 
dosage regimes [17-19]. However, koalas continue to shed the pathogen after treatment with 88 
enrofloxacin [20]. Chloramphenicol is the mainstay of current treatment regimens, although 89 
adverse negative side-effects have been observed [19, 21]. Use of chloramphenicol is further 90 
confounded by its decreasing availability [6], driving the search for alternative antibiotics.  91 
 92 
Florfenicol, a derivative of chloramphenicol, has yielded mixed results as the highest tolerated 93 
dose produced suboptimal plasma concentrations, and the majority of infections required 94 
additional treatments or did not resolve [22]. Doxycycline effectively cleared the infection, but 95 




of the koala, including antimicrobial peptides (AMPs), may play a role in reducing chlamydial 97 
infection and provide avenues for new treatment options in the future.   98 
 99 
There are two main families of AMPs in mammals; cathelicidins and defensins [24]. 100 
Cathelicidins are small, cationic antimicrobial peptides expressed within neutrophils and 101 
epithelial cells, and are features of the innate immune system [24]. They have both 102 
immunomodulatory and antimicrobial functions, and display activity against a range of 103 
bacteria, fungi and viruses [24]. Throughout evolution cathelicidins have expanded in 104 
marsupials, compared to eutherian mammals, resulting in a high number of diverse peptides 105 
[25-28]. For example, the gray short-tailed opossum has 19 cathelicidin genes [27, 28], while 106 
humans have only one [29]. Expansions within marsupials are likely driven by the need to 107 
protect immunologically naive young during pouch life [25, 30]. Marsupials have a very short 108 
gestation period of up to 35 days and give birth to altricial young which are immunologically 109 
naïve at birth [1, 31] . During immunological development the young encounter a diverse range 110 
of microbial flora within the pouch [32], and are protected by products of innate immune 111 
mechanisms such as cathelicidins expressed in the milk [30, 33] and pouch lining [25, 34]. 112 
Previous work has shown that tammar wallaby and Tasmanian devil cathelicidins have potent 113 
broad spectrum antimicrobial activity and kill drug resistant bacteria such as methicillin-114 
resistant S. aureus (MRSA) [30] and multidrug-resistant isolates of Klebsiella pneumoniae, 115 
Pseudomonas aeruginosa and Acinetobacter baumannii [35]. However, activity against 116 
intracellular bacteria such as Chlamydia has not been tested. Cathelicidins from humans and 117 






Our aim was to characterise cathelicidins in the koala genome [40] and transcriptomes [41, 42], 121 
and determine the activity of five synthetic cathelicidins against two koala C. pecorum strains; 122 
IPTaLE and MarsBar, as well as other bacteria and fungi from humans and animals. To further 123 
understand the mechanism of antimicrobial activity, we assessed membrane permeabilisation 124 
and activity in the presence of inhibitors. Cathelicidin transcripts within a range of koala tissue 125 
transcriptomes were examined to determine if cathelicidins are present at the site of chlamydia 126 
infection, and hence may be involved in natural defence against Chlamydia.   127 
Methods 128 
Bioinformatics 129 
Koala cathelicidins were identified in the koala genome [40] and transcriptomes [41, 42] using 130 
BLAST with default parameters, and previously characterised marsupial, monotreme and 131 
eutherian cathelicidins as query sequences (S3 Table). Multiple sequence alignments of 132 
putative koala cathelicidins with sequences from other marsupial, monotreme and eutherian 133 
cathelicidins  (S3 Table) were constructed using ClustalW [43] in BioEdit [44] to identify 134 
conserved peptide domains and motifs. Signal peptide sequences were predicted using SignalP 135 
4.1[45]. To examine phylogenetic relationships, amino acid alignments of full-length 136 
sequences, and cathelin domain only, were used to construct individual phylogenetic trees in 137 
MEGA7 [46] using the neighbour-joining method with p-distance, pairwise deletion and 500 138 
bootstrap replicates, as well as maximum likelihood method, with the Jones Taylor-Thornton 139 
model and 500 bootstrap replicates. Both neighbour-joining and maximum likelihood methods 140 
produced the same tree topology for alignments of full-length sequences and cathelin domain 141 





Only full-length sequences with complete open reading frames were included in subsequent 144 
analyses. The relative transcription levels of full-length koala cathelicidins were examined in 145 
liver, spleen, bone marrow, lymph, lung, kidney, testis, uterus, brain, salivary gland, adrenal 146 
gland, and mammary gland transcriptomes from one koala euthanized due to unsuccessful 147 
treatment for severe chlamydiosis and one koala euthanized due to dog attack [41, 42]. RNAseq 148 
reads (SRR1106690, SRR1106707, SRR1121764, SRR1122141, SRR1203868, SRR1205138, 149 
SRR1205176, SRR1205218, SRR1205222-SRR1205224, SRR1205998, SRR1207974, 150 
SRR1207975, SRR3724381) were mapped against the koala assembly (GCF_002099425.1) 151 
using STAR [47] and abundance estimated using Stringtie [48] as transcripts per million 152 
(TPM). 153 
 154 
Mature peptide cleavage sites were predicted using ExPasy peptide cutter 155 
(http://web.expasy.org/peptide_cutter/) with neutrophil elastase. Molecular weight of mature 156 
peptides and charge at pH7 was calculated using Protein Calculator v3.4 157 
(http://protcalc.sourceforge.net/, May 2013). Hydrophobicity percentage was calculated using 158 
Peptide 2.0 hydrophobicity/hydrophilicity analysis 159 
(http://peptide2.cpm/N_peptide_hydrophobicity_hydrophilicity.php, 2016). Kyte and Dolittle 160 
hydropathicity plots [49] and Deleage and Roux alpha helicity plots [50], both with a window 161 
size of n = 7, were created using ProtScale through the ExPasy server [51]. Grand average of 162 
hydropathicity (GRAVY) scores were calculated using ProtParam through the ExPasy server 163 
[51]. Mature peptide amino acid similarity scores were calculated in BioEdit [44] using the 164 
BLOSUM62 matrix. Mature peptides were synthesised by ChinaPeptides Co. Ltd. to >95% 165 




Antimicrobial susceptibility 167 
Antimicrobial activity was determined against a range of bacteria and fungi from humans and 168 
animals using a broth microdilution susceptibility assay according to clinical laboratory 169 
standards institute (CLSI) guidelines in 96 well polypropylene plates as described previously 170 
[30]. Bacterial and fungal isolates tested are summarised in Table 2. Briefly, cathelicidins were 171 
dissolved in DMSO and serially diluted, in cation- adjusted Mueller Hinton Broth (MH II B) 172 
with or without 10% lysed horse blood for bacteria, and yeast nitrogen base (YNB) for fungi. 173 
Cathelicidin concentrations ranged between 64μg/mL and 0.125µg/mL in a final volume of 174 
100μL. For all bacteria and fungi tested, ampicillin, tetracycline and fluconazole were included 175 
as positive controls, in addition to a media-only control and growth control (no inhibitor). 176 
Bacteria and fungi were sub-cultured 20-24 hours prior to the test, suspended in saline and their 177 
concentration adjusted to a 0.5 McFarland standard. Microorganisms were then diluted to a 178 
concentration of 0.5-1.0x106 cells/mL, with colony counts performed to confirm 179 
microorganism density, and 100µL was dispensed into the wells of the cathelicidin dilution 180 
plate. All plates were incubated at 35oC for 20-48 hours depending on the strain. Antimicrobial 181 
activity was expressed as minimum inhibitory concentration (MIC), which was defined as the 182 
lowest concentration of cathelicidin preventing visible bacterial growth, relative to the no-drug 183 
control. The same microdilution susceptibility assay was performed using Mueller Hinton 184 
Broth without the addition of the divalent cations calcium and magnesium (MHB), to test the 185 
effect of the cations on PhciCath5 activity against the ATCC strains E. coli 25922 and S. aureus 186 
29213.  187 
 188 
Effect of serum and blood on antibacterial activity 189 
The potential inhibitory effect of serum and blood on PhciCath5 antibacterial activity was 190 




with the following modifications. PhciCath5 was solubilized in water for cell culture containing 192 
0.01% acetic acid and serial two-fold dilutions were prepared from 50mM to 0.78mM. E. coli 193 
ATCC25922 was sub-cultured onto sheep blood agar (SAB) and incubated at 35oC for 24 hours 194 
prior to the test. Colonies were suspended in saline and the concentration adjusted to a 0.5 195 
McFarland standard. The bacterial suspension was then diluted 1/250 with MHB containing 196 
10% bovine serum albumin (BSA) or 20% whole mouse blood. The cathelicidin serial dilutions 197 
were further diluted 1/10 with bacterial suspension in a 96-well polypropylene plate, to give a 198 
final cathelicidin concentration ranging between 50 and 0.78µM. A growth control (no 199 
inhibitor) was also included. The plates were incubated for 24 hours at 37oC and the MIC 200 
recorded as the lowest concentration of cathelicidin preventing visible bacterial growth, 201 
relative to the no-drug control. 202 
 203 
Bacterial membrane permeability 204 
Membrane permeabilisation of E. coli ATCC25922 by PhciCath5 was assessed using the 205 
Promega CellTox green cytotoxicity assay. E.coli ATCC25922 was sub-cultured onto TSA II 206 
blood agar and incubated at 35oc for 24 hours prior to the test. A bacterial suspension was 207 
prepared in RPMI to give an OD600 reading of 0.2. PhciCath5 was dissolved in water for cell 208 
culture containing 0.01% acetic acid and serial two-fold dilutions prepared in a black 384-well 209 
polypropylene plate. The plate was then innoculated with E. coli ATCC25922, producing a 210 
total well volume of 30uL and final peptide concentration of 50 to 0.05uM. Fluorescence was 211 
then measured at 512nm using the Perkin Elmer Envision multilabel plate reader (0 hours). The 212 
plate was then incubated at room temperature and additional fluorescence measurements were 213 
recorded at 1, 2, 3 and 4hrs. Membrane permeability was calculated as a percentage relative to 214 
the “no inhibitor” control. PhciCath5 concentration which resulted in greater than or equal to 215 
5% E. coli ATCC25922 membrane permeability was reported.  216 
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Chlamydia pecorum antimicrobial susceptibility 218 
C. pecorum IPTaLE and MarsBar [11, 52] were cultured in mouse McCoy B cells, on DMEM 219 
supplemented with 10% foetal calf serum (FCS), 0.1mg/mL streptomycin and 0.05mg/mL 220 
gentamicin at 37oC in a 5% CO2 atmosphere. Cell lines were routinely tested for mycoplasma 221 
contamination every 2 months. Prior to performing antimicrobial susceptibility assays, 96-well 222 
microtitre plates seeded with 30,000 host cells per well 24 hours prior to chlamydial infection 223 
as described previously [53, 54]. For the antimicrobial assays, koala cathelicidin mature 224 
peptides, PhciCath1, 2, 3, 5 and 6, were solubilized in water for cell culture with 0.01% acetic 225 
acid, and two-fold dilutions were made in sucrose-phosphate-glutamic acid (SPG) media from 226 
1mg to 250μg/mL, in triplicate. Cathelicidin containing wells were diluted one in two with C. 227 
pecorum IPTaLE and MarsBar and incubated for 2 hours at 37oC, giving a final cathelicidin 228 
concentration of 500, 250 and 125μg/mL. A negative SPG only control was included. To 229 
exclude the possibility of cathelicidin toxicity to McCoy cells, cathelicidin dilutions were 230 
removed by centrifugation and C. pecorum re-suspended in DMEM supplemented with10% 231 
FCS, 0.1mg/mL streptomycin and 0.05mg/mL gentamycin. The suspension was used to infect 232 
a McCoy B ATCC CRL-1696 cell monolayer at a Multiplicity of Infection (MOI) of 0.6 as 233 
described previously [53, 54]. At 44 hours post infection, host cells were lysed by vigorous 234 
pipetting and Chlamydia harvested by centrifugation. Following one freeze-thaw passage of 235 
the supernatant, Chlamydia were serially diluted onto fresh McCoy cell monolayers, and fixed 236 
and stained at 40hrs post infection for enumeration of Chlamydia inclusion forming units (IFU) 237 
per mL. This approach involving two rounds of infection essentially provides the minimum 238 
chlamydicidal concentration, or the minimum concentration of cathelicidin required to kill the 239 
EB. Monolayers were stained with DAPI, a polyclonal HtrA antibody and secondary antirabbit 240 




Statistical analysis was performed on the Prism GraphPad software [55]. A one-way ANOVA 242 
followed by a Holm-Sidak’s multiple comparisons test was performed relative to the control.  243 
 244 
Results and Discussion 245 
Characterisation of koala cathelicidins expressed in different 246 
tissues 247 
Ten cathelicidins were identified within a 1.3Mb region on scaffold 76 of the koala genome, 248 
and were named in order of identification (S1 Table). Five cathelicidins, PhciCath1, 2, 3, 5 and 249 
6, were full-length and contained complete open reading frames. One cathelicidin, PhciCath4, 250 
contained a premature stop codon in exon 3 and hence is likely to be a pseudogene. Only partial 251 
sequences could be identified for four cathelicidins, PhciCath7, 8, 9 and 10. 252 
 253 
All koala cathelicidins contained sequence features characteristic of the cathelicidin family (S1 254 
Fig) [24]. Koala cathelicidin genes contained four exons, which encode a prepropeptide 255 
consisting of three domains. The signal peptide and cathelin domain contained conserved 256 
stretches of sequence, including four cysteine residues in the latter which are a distinguishing 257 
feature of the family and provide structure to the prepropeptide (S1 Fig) [24]. For PhciCath1, 258 
2, 3, 5 and 6 with full-length sequences, the antimicrobial domain which encodes the mature 259 
peptide was variable in length and composition (Table 1), with a maximum 30% amino acid 260 
similarity amongst the five predicted mature peptide sequences (S1 Table). Tasmanian devil 261 
cathelicidins also display a similar level of variability in this domain, however in eutherian 262 





Table 1. Physiochemical properties of predicted mature peptides from full-length koala 264 

































3751.71 0.9 44.12 0.106 
 
Koala cathelicidins cluster with other marsupial cathelicidins in the phylogenetic tree, as 266 
expected (Fig 1). PhciCath1, 3 and 6 form direct orthologs with MaeuCath8, SahaCath1 and 267 
ModoCath8 respectively, indicating that these genes arose prior to speciation and have been 268 
conserved throughout evolution. PhciCath2 and 5 cluster within a marsupial-specific clade, 269 
sister to that containing eutherian cathelicidins (Fig 1). Interestingly, PhciCath5 is located in 270 
the clade containing SahaCath3, 5 and 6, ModoCath4, and MaeuCath1 and 7 (Fig 1), all of 271 
which display antimicrobial activity [30, 35, 56]. Focusing on the conserved cathelin domain, 272 
the inclusion of partial koala sequences PhciCath7p to 10p does not influence the clustering of 273 
koala cathelicidins (S2 Fig). Although, PhciCath5 now clusters with PhciCath7p to 10p within 274 
the marsupial clade, forming a koala-specific expansion. The short branch lengths of 275 
PhciCath5 and PhciCath7p to 10p indicate that these genes likely arose through more recent 276 
duplications, compared to PhciCath1, 2, 3 and 6 (S2 Fig). Although, PhciCath7 to 10 may 277 
represent pseudogenes and hence not accurately portray phylogeny of functional koala 278 
cathelicidins.  279 
 
 
























Fig 1.  Full-length koala cathelicidins cluster with other marsupials in the phylogenetic 280 
tree, particularly PhciCath5 which clusters with other marsupial cathelicidins that 281 
display antimicrobial activity. Sequences are coloured according to antimicrobial activity 282 
against bacteria and/or fungi; green indicates active, red indicates inactive and black indicates 283 
the peptide has not been tested. Only bootstrap values greater than 50% are shown. Accession 284 
numbers for published sequences used in this tree are available in S3 Table.   285 
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Only full-length cathelicidins PhciCath1, 2, 3, 5 and 6 were included in subsequent analyses 287 
as without the full coding sequence, partial sequences of PhciCath7 to 10 could represent 288 
pseudogenes. Koala cathelicidins were transcribed in numerous tissues, similar to other 289 
marsupial [30, 35] and eutherian cathelicidins [57]. Cathelicidin transcripts were detected in 290 
respiratory, cardiovascular, immune, reproductive and excretory tissues from two wild koalas 291 
(Fig 2) [42]. PhciCath1 had the greatest expression of any cathelicidin and the greatest 292 
breadth, with transcripts present in all fifteen tissue transcriptomes (Fig 2). This broad 293 
expression of cathelicidins within multiple organ systems is likely derived from epithelial 294 
cells, which in humans constitutively express cathelicidins [57]. Here they likely provide 295 
rapid defence against infection, without the lag imposed by the recruitment and activation of 296 

























Fig 2. Expression of full-length koala cathelicidins in twelve tissue transcriptomes from 298 
two individuals [41, 42]. Expressed as transcripts per million (TPM).  299 
 300 
With the exception of PhciCath1, cathelicidin expression is favoured in immune tissues over 301 
non-immune tissues, although variation between the two individuals is marked (Fig 2). All five 302 
cathelicidins PhciCath1, 2, 3, 5 and 6 were expressed in the bone marrow, likely due to the 303 
presence of neutrophil precursors as observed in humans [58] and guinea pigs [59]. Expression 304 
of cathelicidins within neutrophils changes throughout cell development, and peaks during the 305 
myelocyte and metamyelocyte stage within the bone marrow [58, 59]. Tammar wallaby 306 
MaeuCath1 was also expressed in the bone marrow, and peak expression coincided with 307 
maturation of immune organs in pouch young [25]. All koala cathelicidins except PhciCath2 308 
were expressed in the lymph node, and a high number of PhciCath3 transcripts were present 309 
in the spleen (Fig 2). A high level of cathelicidin expression within koala immune tissues is not 310 
surprising given their localised expression within neutrophils and epithelial cells, and similar 311 





 PhciCath1 and 6 proteins were present in the koala milk proteome, along with PhciCath3 314 
transcripts in the mammary gland [41], and hence may provide a direct source of immune 315 
compounds to developing young. Similar findings were reported by Morris et al. (2016) where 316 
cathelicidins were detected in a koala early lactation mammary gland transcriptome and late 317 
lactation milk proteome [41]. Cathelicidins were relatively abundant in late lactation, 318 
comprising 1.1% of peptides [41]. Tasmanian devil milk also contained cathelicidins [30], 319 
similarly tammar wallaby cathelicidins were expressed in the mammary gland throughout 320 
lactation [35]. The presence of cathelicidins within the milk of three marsupial species suggests 321 
this feature is well conserved across different marsupial lineages, indicating these peptides may 322 
play an essential role in pouch young protection and development [25, 30].  323 
 324 
Koala cathelicidin PhciCath5 shows direct antimicrobial activity 325 
Koala cathelicidin PhciCath5 was the only peptide to display antimicrobial activity when 326 
screened against representative Gram negative and positive bacterial strains, with the most 327 
potent activity detected against E. coli (MIC 16μg/mL) and S. aureus (8μg/mL) isolates (Table 328 
2). PhciCath5 also displayed antifungal activity against the ATCC strains Candida parapsilosis 329 
22019 and Candida krusei 6258. The spectrum of activity was similar to that of other marsupial 330 
[30, 35, 60] and monotreme  [35, 60] cathelicidins. PhciCath5 was also active against the test 331 
strain of methicillin-resistant Staphylococcus aureus (MRSA) with an MIC of 16μg/mL. This 332 
MIC value is more potent than Tasmanian devil SahaCath5 against the same MRSA isolate 333 
[30], and within the range of MICs reported for human, bovine and rabbit cathelicidins against 334 
different MRSA isolates [61]. MRSA is a pathogen of major concern to human health [62], and 335 
antimicrobials such as cathelicidins provide novel alternatives for development as they 336 




Table 2. Koala cathelicidin mature peptide PhciCath5 displays antimicrobial activity 338 
against bacteria and fungi from humans and animals, expressed as the minimum 339 
inhibitory concentration (MIC). The MIC of PhciCath1, 2, 3 and 6 was >64ug/mL for all 340 
bacteria and fungi tested. *denotes animal isolate, otherwise human clinical isolates and 341 
ATCC strains were tested. MICs were obtained using MH II B that contains magnesium and 342 
calcium divalent cations. MICs in brackets were obtained using MHB without the additional 343 
of aforementioned divalent cations. a denotes MICs obtained using MHB with 10% foetal 344 






P. aeruginosa* >64 
P. aeruginosa ATCC27853 >64 
E. coli* 16 
E. coli ATCC25922 64 (11) 
22a 
>175b 
S. aureus* 8 
S. aureus ATCC29213 16 (11) 
MRSA* 16 
S. pneumoniae ATCC49619 >64 
S. pyogenes ATCC19615 64 
S. agalactiae ATCC12386 64 
S. agalactiae* 64 
S. dysgalactiae >64 
S. lutetiensis >64 
S. equi* >64 
S. oralis >64 
S. salivarius 64 
S. mutans >64 
L. monocytogenes* 64 
P. multocida* >64 
K. pneumoniae* >64 
C. parapsilosis ATCC 22019 32 
C. krusei ATCC 6258 64 
C. glabrata >64 





Despite this promising activity profile in vitro, multiple inhibitors present within the in vivo 346 
environment are known to influence antimicrobial activity. Indeed, antibacterial activity of 347 
PhicCath5 against the E. coli ATCC strain was neutralised in 20% whole blood, resulting in an 348 
increase in the MIC from 64 μg/mL  to >175μg/mL, and a reduction in the MIC in 10% FCS 349 
from 22μg/mL to 11μg/mL (Table 2). This indicates that PhciCath5 binds non-specifically to 350 
proteins within the blood, sequestering the peptides, or is enzymatically degraded, both of 351 
which have been documented within human [64], rabbit and sheep cathelicidins [65]. 352 
 353 
As observed in eutherian cathelicidins [66, 67], adherence of PhciCath5 to pathogens was 354 
facilitated by electrostatic interactions between positively charged cathelicidins and negatively 355 
charged head groups on the surface of bacterial cell membranes . Divalent cations bind to the 356 
negatively charged head groups, thereby preventing interaction with positively charged 357 
cathelicidins [68]. This is evidenced by a reduction in antimicrobial activity following the 358 
addition of magnesium and calcium divalent cations to the media. The MIC of PhciCath5 359 
against E. coli increased five-fold in the presence of divalent cations, while the effect on the 360 
MIC against S. aureus was less pronounced (Table 2). . Given that electrostatic interaction 361 
enables pathogen adherence, a high cationic charge often correlates with antimicrobial activity 362 
amongst many eutherian cathelicidins [69], however we found no such association amongst 363 
koala cathelicidins.  364 
 365 
Following electrostatic attachment, PhciCath5 rapidly permeabilised bacterial cell membranes 366 
at high concentrations. At 44μg/mL, four times the MIC of 11μg/mL, PhciCath5 permeabilised 367 
5% of the E. coli cell membrane, leading to cell death within an hour of treatment. However 368 
at the MIC, PhciCath5 is slow-acting, as the same level of membrane permeabilisation was 369 




which rapidly killed bacteria at the MIC within 15 minutes [35]. The ability of eutherian 371 
cathelicidins to permeabilise bacterial cell membranes has been linked to an amphipathic alpha 372 
helical peptide structure [29, 64, 69]. The potent MaeuCath1 also forms an amphipathic alpha 373 
helix according to the predictive algorithms of Kyte and Doolittle, and Deleage and Roux [33, 374 
35]. Both algorithms suggest the same structure for PhciCath5 as observed in Fig 3, with two 375 
alpha helical regions indicated by the scores rising above the 0.99 cutoff. While the negative 376 
GRAVY score suggests PhciCath5 is hydrophilic (Table 1), the Kyte and Doolittle 377 
hydropathicity plot reveals that PhciCath5 is amphipathic (Fig 3). Hydrophilic residues span 378 
the middle of PhciCath5, with hydrophobic regions at the N and C-terminus. While PhciCath5 379 
and MaeuCath1 both contain amphipathic alpha helical regions, additional physiochemical 380 
properties such as cationicity and sequence composition influence antimicrobial activity, and 381 
may explain the difference in activity and rate of permeabilisation between the two 382 

































Fig 3. PhciCath5 contains two predicted alpha helical regions (A) and is amphipathic, 384 
with hydrophilic residues spanning the middle of the peptide and hydrophobic residues 385 
at the N- and C-terminus (B).  386 
 387 
Permeabilisation of bacterial membranes by amphipathic alpha helical cathelicidins can be 388 
described by two models; the barrel stave model and the carpet model [66]. In the barrel stave 389 
model, aggregates of cathelicidins insert into the membrane and form transmembrane pores, 390 
thereby enabling leakage of essential molecules and disrupting transmembrane potential. 391 
Amphipathicity facilitates membrane insertion, as the hydrophobic surface of the peptide 392 
interacts with the lipid core of the bacterial cell membrane, and the hydrophilic surface forms 393 




Instead cathelicidins bind to the surface of the membrane until a threshold concentration is 395 
reached, which disrupts the curvature of the membrane leading to destabilisation [66]. These 396 
results are speculative, and lipid membrane models would be required to confirm the 397 
mechanism of PhciCath5 membrane permeabilisation.   398 
 399 
Koala cathelicidins PhciCath1, 2, 3 and 6 were inactive against all bacteria and fungi included 400 
in our assays at the concentrations tested. However, given the diversity and complexity of 401 
marsupial microbiomes known to contain novel and uncharacterised taxa [71-73], it is possible 402 
that they may have activity against specific bacteria and fungi not tested in this study. Some 403 
marsupial cathelicidins have shown been found to show selective activity, such as Tasmanian 404 
devil SahaCath3 which was only active against Cryptococcus neoformans [30]. However, 405 
PhciCath1, 3 and 6 are orthologous to marsupial cathelicidins which do not display 406 
antimicrobial activity (Fig 1) [26, 60]. Conservation of PhciCath1, 2, 3 and 6 suggests an 407 
essential function that has been conserved throughout marsupial evolution. The high level of 408 
expression in immune tissues (Fig 2) supports a role in modulating the immune response. While 409 
the immunomodulatory functions of marsupial cathelicidins remain to be tested, eutherian 410 
cathelicidins are chemotactic to various immune cells, modulate immune cell development and 411 
alter cytokine expression profiles [24].  412 
 413 
PhciCath5 is active against Chlamydia pecorum  414 
Koala cathelicidin PhciCath5 inactivated C. pecorum MarsBar and IPTaLE elementary bodies 415 
(EB) and was the only peptide tested that caused biologically and statistically significant 416 
reductions in chlamydial inclusions. Treatment with 125μg/mL of PhciCath5 resulted in a more 417 
than 2 orders of magnitude decrease in infectious progeny of both C. pecorum serovars, 418 




500μg/mL, with less than half an order of magnitude difference in chlamydial inclusions 420 
compared with the control. Other marsupial cathelicidins have not been tested for anti-421 
chlamydial activity and only a handful of studies have tested eutherian cathelicidins. They 422 
revealed a wide variation in activity between chlamydial species and serovars [36, 37, 74, 75].  423 
Cathelicidins from humans and livestock inactivated a number of C. trachomatis isolates [36-424 
39, 74, 75], especially pig protegrin PG-1 which reduced the infectivity of C. trachomatis at 425 
1.25μg/mL [75]. Comparison of these results with koala cathelicidins presented in this study 426 
indicate the anti-chlamydial activity of PhciCath5 against C. pecorum is moderate at most, 427 
given PhciCath5 was active at over 100-fold higher concentration than PG-1, albeit against 428 
different Chlamydia species. However, experimental conditions used by Yasin et al 1996 429 
differed from our study, as only a single round of infection was performed, and the reduction 430 
in inclusions or change in inclusion morphology measured. This is effectively a MIC, or the 431 
minimum cathelicidin concentration required to inhibit formation of chalmydial inclusions, but 432 
may not have killed the EB. In this study we conducted two rounds of infection, then measured 433 
the reduction in chlalmydial infectivity. As such, our results effectively represent the minimum 434 
chalmydicidal concentration (MCC), or the minimum concentration of PhciCath5 which killed 435 
EB and hence reduced chalmydial infectivity [74]. Furthermore, the same eutherian 436 
cathelicidins which have activity against C. trachomatis were ineffective against one C. 437 
pecorum isolate at a maximum concentration of 80ug/mL [37]., Hhowever, eutherian 438 
cathelicidins have not been extensively tested against this Chlamydia species. Despite this, it 439 
is possible that koala cathelicidins evolved anti-chlamydial activity in response to host-440 






Fig 4. Activity of koala cathelicidins PhciCath1, 2, 3, 5 and 6 against C. pecorum MarsBar 442 
(A) and IPTaLE (B) at 125μg/mL. Expressed as inclusion forming units (IFU) per mL.  **** 443 
indicates p<0.0001 significance was identified.  444 
 445 
Koala PhciCath5 acted directly upon, and rapidly inactivated C. pecorum MarsBar and IPTaLE 446 
EB. Removal of cathelicidins through centrifugation prior to chlamydial infection of the cell 447 
monolayer suggests PhciCath5 most likely induces permanent damage to the EBs within 2 448 
hours, rather than preventing EB uptake into the host cell. Similar results were observed for 449 
pig protegrin-1 (PG-1) against three C. trachomatis serovars after a single round of infection 450 
[75]. This study revealed that PG-1 interacted directly with EBs and caused significant 451 
morphological changes, including membrane damage, loss of cytoplasm and nucleus [75]. 452 
Given that Chlamydia is a Gram-negative bacterium, PhciCath5 may affect membrane 453 
permeability as it did in E. coli. However, Chlamydia EB have a strong, cross-linked outer 454 
membrane which differs substantially from the outer membrane of E. coli [75]. Given 455 
PhciCath5 is a small peptide, only 31 residues in length, it may be able to penetrate through 456 
these structures and bind to the outer membrane of C. pecorum.  457 
 458 
Commented [WH3]: Do you have a figure or table for the 
treatment of EBs? Or am I not remembering our experiments 
correctly? 
Commented [EP4R3]: I don't have any figures/tables for 




Given these results, why are koalas with chlamydiosis unable to clear C. pecorum infection 459 
naturally? PhciCath5 and other koala cathelicidins may be present at the site of Chlamydia 460 
infection, secreted from epithelial cells or infiltrating immune cells. This is evidenced by 461 
expression in immune tissues such as the bone marrow, lymph node and spleen (Fig 1). 462 
Cathelicidins are expressed within neutrophils, lymphocytes and macrophages [76], all of 463 
which infiltrate the submucosa of the conjunctiva, urogenital and reproductive tract of the koala 464 
during infection [77]. However, it is unlikely that PhciCath5 reaches the effective concentration 465 
of 125μg/mL in vivo which inactivated EB in vitro. The human cathelicidin LL-37 is present 466 
in plasma at a concentration of 1.2μg/mL [78] and bronchioalveolar lavage fluid up to 15μg/mL 467 
[79]. As PhciCath5 was effective in vitro at up to 100 times this concentration, cathelicidin 468 
expression at the site of infection in vivo may not be adequate to influence the progression of 469 
Chlamydia infection. Further work is required to quantify cathelicidin concentration at the site 470 
of infection in order to determine susceptibility in vitro at a representative concentration.  471 
 472 
Our results show PhciCath5 has activity against extracellular EB. Timing of cathelicidin release 473 
from immune and epithelial cells within the host may not enable direct interaction with EB. 474 
Intracellular Chlamydia may be more resistant to cathelicidin attack, as treatment of 475 
intracellular C. trachomatis with PG-1 resulted in a 67% reduction in infectivity, compared to 476 
almost 100% reduction following treatment of extracellular EBs [74]. Indeed, proteases 477 
secreted by this C. trachomatis neutralise LL-37 anti-chlamydial activity, thereby evading 478 
AMP attack and ensuring extracellular EB survival. Chlamydia protease-like factor (CPAF) 479 
[38] and Chlamydia high temperature requirement protein A (cHtrA) [39] both specifically 480 
degrade LL-37. Whereas the plasmid encoded virulence factor pgp3 binds to, and forms stable 481 
complexes with LL-37, neutralising anti-chlamydial activity [80]. Interestingly, pgp3 also 482 




promotes Chlamydia survival [81]. Pgp3 also uses LL-37 to enhance its own pro-inflammatory 484 
activity on neutrophils, which may aid Chlamydia spreading [81]. CPAF, cHtrA and pgp3 are 485 
secreted into the cytoplasm of infected host cells and released upon host cell lysis, degrading 486 
or neutralising extracellular LL-37 before exposure of intra-inclusion EB [38, 39, 81]. Similar 487 
AMP evasion strategies have not been investigated in C. pecorum. However, given results in 488 
C. trachomatis, there is potential for the anti-chlamydial activity of PhciCath5 to be inactivated 489 
in vivo.  490 
 491 
Drug development potential 492 
The broad- spectrum activity of PhciCath5 against bacteria and fungi, including drug-resistant 493 
MRSA, as well as C. pecorum suggests that it shows promise for development as a therapeutic. 494 
Peptide modification is required to identify pinpoint residues responsible for antimicrobial 495 
activity, and those involved in non-specific binding to blood proteins, similar to the alanine 496 
scans performed for LL-37 and derivatives [82, 83]. Additional assays are required to assess 497 
mammalian cell toxicity, one of the main barriers to cationic peptide development. A number 498 
of marsupial cathelicidins are cytotoxic, although mainly at concentrations far above the MIC 499 
[26, 60]. Many eutherian cathelicidins are currently under pharmaceutical development as 500 
topical agents because they were associated with toxicity, low tissue penetration and peptide 501 
degradation when trialled for systemic use [84]. Derivatives of LL-37 and bovine indolicidin 502 
are currently in development as topical agents, while a topical formulation of PG-1 derivative 503 
known as Iseganan has reached phase III clinical trials for the treatment of oral mucositis [84]. 504 
Topical antibiotics are commonly used for the treatment of ocular chlamydiosis in koalas due 505 
to ease of application [85], hence topical cathelicidin formulations may provide alternative 506 





Synergy between cathelicidins and traditional antibiotics has resulted in increased 508 
antimicrobial activity [24]. Perhaps the same is true for PhciCath5 and chloramphenicol, which 509 
is commonly used to treat chlamydiosis in koalas [21]. Given its broad-spectrum activity, 510 
topical application of PhciCath5 may also prevent or reduce secondary infections involving 511 
Gram-negative and Gram-positive bacteria or fungi, which have been reported in koala 512 
chlamydiosis [85].   513 
Conclusions 514 
We characterised ten cathelicidins in the koala, five of which were full-length sequences that 515 
were widely expressed in tissues throughout the body. One cathelicidin, PhciCath5 displayed 516 
broad-spectrum antimicrobial activity against representative bacteria and fungi, including drug 517 
resistant strains. The activity of the remaining four cathelicidins may be highly specific or 518 
immunomodulatory. When tested against Chlamydia, PhciCath5 significantly reduced the 519 
infectivity of C. pecorum IPTaLE and MarsBar by rapidly inactivating elementary bodies prior 520 
to infection. Despite this, PhciCath5 may be unable to prevent or control C. pecorum infections 521 
in koalas due to inadequate peptide concentration at the site of infection, timing of peptide 522 
release or production of AMP-degrading proteases by Chlamydia. PhciCath5 represents a lead 523 
for antimicrobial development, with additional work required to confirm the absence of 524 
toxicity, explore potential synergistic effects with current antibiotics, and introduce peptide 525 
modifications to enhance antimicrobial activity. 526 
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Supporting information 768 
 769 
S1 Fig. Multiple sequence alignment of koala cathelicidins with other marsupial and 770 
eutherian cathelicidins. PhciCath4 was not included in the alignment as it contains a 771 
premature stop codon and hence is a likely a pseudogene. PhciCath7p to 10p are partial 772 
sequences only, as the mature peptide could not be identified. The predicted signal peptide 773 
sequence is underlined, followed by two domains; the cathelin domain which contains 774 
conserved cysteine residues (boxed), and the antimicrobial domain which encodes the mature 775 
peptide and is of variable length and composition. The predicted mature peptide cleavage site 776 
is denoted by a star. 777 
 778 
S2 Fig. Koala cathelicidins cluster with other marsupials in the phylogenetic tree. The 779 
koala-specific expansion containing PhciCath5, and 7p to 10p, clusters with other 780 
marsupial cathelicidins this display antimicrobial activity. Sequences are coloured 781 
according to antimicrobial activity against bacteria and/or fungi; green indicates active, red 782 
indicates inactive, black indicates peptide has not been tested. Only bootstrap values greater 783 
than 70% are shown. Accession numbers for sequences used are available in S3 Table. 784 
 785 
S1 Table. Amino acid similarity amongst koala cathelicidin mature peptide sequences.   786 
 787 





S3 Table. Sequence accession numbers used in BLAST searches and phylogenetic trees. 790 
See Fig. 3 and S2 Fig.   791 
